by Admin | Aug 30, 2022 | Portfolio News
— 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection — — BA.5 neutralizing antibody levels were approximately...
by Admin | Aug 29, 2022 | Portfolio News
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study...
by Admin | Aug 29, 2022 | Portfolio News
— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents,...
by Admin | Aug 2, 2022 | Portfolio News
Shanghai/August.1st, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate...
by Admin | Apr 12, 2022 | Portfolio News
First regulatory milestone as part of a strategy to advance patient care April 11, 2022 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that...
by Admin | Feb 16, 2022 | Delos News
HONG KONG, Feb. 15, 2022 /PRNewswire/ — Delos Capital, a Hong Kong-headquartered life sciences venture capital fund with a global presence and investment mandate, announces the successful $300 million first close of its Fund III....
by Admin | Jan 14, 2022 | Portfolio News
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royaltiesADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and NorwayCefepime/enmetazobactam has...
by Admin | Dec 16, 2021 | Portfolio News
MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis...
by Admin | Dec 9, 2021 | Portfolio News
Platform combines the innate immuno-stimulatory effect of the myxoma virus with anti-tumor immune stimulation that uniquely target multiple aspects of cancer immunity to treat solid tumors and hematological cancersOncoMyx is developing a next generation oncolytic...
by Admin | Nov 4, 2021 | Portfolio News
– Financing round was co-led by GordonMD Global Investment LP – Funding will support the Phase 2b clinical program of ATI-2173 in HBV MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical...
